259 completed, 86 terminated, 30 unknown, 28 active not recruiting. 271 Phase 2, 153 Phase 1, 48 Phase 3, 9 Phase 4, 7 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 271 | Completed 154, Terminated 59, Unknown 21, Active not recruiting 14, Withdrawn 13, Recruiting 8, Not yet recruiting 2 |
| Phase 1 | 153 | Completed 103, Terminated 27, Unknown 7, Withdrawn 7, Active not recruiting 6, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 48 | Completed 20, Active not recruiting 10, Terminated 6, Unknown 6, Recruiting 5, Not yet recruiting 1 |
| Phase 4 | 9 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Not applicable | 7 | Completed 5, Terminated 2 |
| Early Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | 88 | 2026-09-03 | 2026-09-03 |
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | 1708 | 2026-08-28 | 2026-07-30 |
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | 90 | 2026-07-30 | 2026-08-17 |
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Venetoclax, Dexamethasone, Bortezomib - T-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 | Recruiting | 18 | 2026-06-05 | 2026-08-12 |
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma | Phase 2 | Recruiting | 200 | 2026-04-15 | 2026-08-25 |
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone - Myeloma Multiple | Phase 2 | Recruiting | 74 | 2026-03-05 | 2026-09-14 |
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma | Phase 3 | Recruiting | 508 | 2026-02-23 | 2026-09-29 |
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Iberdomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | 75 | 2024-12-12 | 2026-08-31 |
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | 58 | 2024-07-23 | 2026-09-25 |
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis | Phase 3 | Recruiting | 338 | 2024-07-01 | 2026-05-06 |
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Bortezomib, Pomalidomide, Dexamethasone - Systemic Amyloidosis | Phase 2 | Recruiting | 40 | 2024-05-06 | 2024-12-30 |
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Talquetamab, Pomalidomide, Teclistamab - Multiple Myeloma | Phase 3 | Active not recruiting | 838 | 2024-01-22 | 2026-09-25 |
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Unknown | 200 | 2023-11-23 | 2024-04-23 |
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Daratumumab, Carfilzomib, Lenalidomide - Multiple Myeloma, Primary Plasma Cell Leukemia | Phase 2 | Recruiting | 54 | 2023-10-20 | 2025-04-16 |
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Recruiting | 510 | 2023-10-12 | 2026-06-10 |
CURATE.AI Optimized Modulation for Multiple Myeloma
Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | 20 | 2023-09-10 | 2023-09-06 |
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 3 | Completed | 514 | 2023-04-14 | 2026-02-18 |
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | 10 | 2022-10-07 | 2026-05-13 |
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
mezigdomide, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | 810 | 2022-09-20 | 2026-09-30 |
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | 49 | 2022-08-11 | 2026-10-16 |
Showing 20 of 441. Sign in to see all of them.
Conditions studied
Multiple Myeloma (205) · Lymphoma, Mantle-Cell (39) · Lymphoma (29) · Leukemia, Myeloid, Acute (27) · Lymphoma, Follicular (26) · Lymphoma, Non-Hodgkin (26) · Recurrence (26) · Neoplasms, Plasma Cell (24) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Lymphoma, Large B-Cell, Diffuse (20) · Leukemia, Lymphocytic, Chronic, B-Cell (18) · Waldenstrom Macroglobulinemia (17) · Lymphoma, B-Cell, Marginal Zone (14) · Leukemia (13) · Carcinoma, Non-Small-Cell Lung (12)
Sponsors
National Cancer Institute (NCI) (73) · M.D. Anderson Cancer Center (23) · Dana-Farber Cancer Institute (15) · University of Arkansas (14) · Millennium Pharmaceuticals, Inc. (10) · Emory University (9) · Janssen Research & Development, LLC (9) · Mayo Clinic (8) · Massachusetts General Hospital (6) · City of Hope Medical Center (5) · Duke University (5) · Masonic Cancer Center, University of Minnesota (5) · UNC Lineberger Comprehensive Cancer Center (5) · University of Michigan Rogel Cancer Center (5) · Barbara Ann Karmanos Cancer Institute (4)
Countries
United States (326) · Germany (27) · France (26) · Spain (26) · Canada (24) · China (24) · Italy (24) · South Korea (19) · Greece (18) · Australia (17) · United Kingdom (17) · Czechia (13) · Poland (13) · Brazil (12) · Netherlands (12)
Top investigators
Maurizio Zangari, MD (5) · E. Steve Woodle, MD (4) · Irene Ghobrial, MD (4) · Arkadiusz Dudek, MD (3) · Joanne Filicko-O'Hara, MD (3) · Paul Richardson, MD (3) · Vaishali Sanchorawala, MD (3) · Amine Bensmaine, MD (2) · Andrzej J Jakubowiak, MD, PhD (2) · Angela Davies (2) · Arlene Siefker-Radtke, MD (2) · Bart Barlogie, MD, PhD (2)
Results publications
PMID 33357481, PMID 22689675, PMID 40501401, PMID 29567784, PMID 22674807, PMID 23305732, PMID 23603914, PMID 23897961, PMID 28419486, PMID 34289038, PMID 35876974, PMID 36184192, PMID 37990162, PMID 39321347, PMID 39863139, PMID 15613697, PMID 18327587, PMID 19104417, PMID 19498019, PMID 19528374, PMID 19692142, PMID 19860608, PMID 19884643, PMID 20012045, PMID 20142586, PMID 20582937, PMID 20661232, PMID 20807892, PMID 20952514, PMID 20956803, PMID 21098740, PMID 21146205, PMID 21228328, PMID 21239695, PMID 21241279, PMID 21345726, PMID 21562045, PMID 21596852, PMID 21791469, PMID 21816833, PMID 21911830, PMID 21951682, PMID 21990396, PMID 22394984, PMID 22498745, PMID 22535574, PMID 22566605, PMID 22653976, PMID 22733020, PMID 22773122
NIH funding
U10CA021115 (9), U10CA031946 (7), N01CM62204 (5), U01CA076576 (5), U10CA032102 (5), U10CA098543 (5), U10CA180820 (5), 2005 (4), N01CM62205 (4), P30CA015083 (4), U01CA062505 (4), U10CA180821 (4), U10CA180886 (4), U10CA180888 (4), 2008 (3)